International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction.
Published: 8th November 2017
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
The aim was to carry out phase 4 international field‐testing of the European Organisation for Research and Treatment of Cancer (EORTC) breast reconstruction (BRECON) module. The primary objective was finalization of its scale structure. Secondary objectives were evaluation of its reliability, validity, responsiveness, acceptability and interpretability in patients with breast cancer undergoing mastectomy and reconstruction.
The EORTC module development guidelines were followed. Patients were recruited from 28 centres in seven countries. A prospective cohort completed the QLQ‐BRECON15 before mastectomy and the QLQ‐BRECON24 at 4–8 months after reconstruction. The cross‐sectional cohort completed the QLQ‐BRECON24 at 1–5 years after reconstruction, and repeated this 2–8 weeks later (test–retest reliability). All participants completed debriefing questionnaires.
A total of 438 patients were recruited, 234 in the prospective cohort and 204 in the cross‐sectional cohort. A total of 414 reconstructions were immediate, with a comparable number of implants (176) and donor‐site flaps (166). Control groups comprised patients who underwent two‐stage implant procedures (72, 75 per cent) or delayed reconstruction (24, 25 per cent). Psychometric scale validity was supported by moderate to high item‐own scale and item‐total correlations (over 0·5). Questionnaire validity was confirmed by good scale‐to‐sample targeting, and computable scale scores exceeding 50 per cent, except nipple cosmesis (over 40 per cent). In known‐group comparisons, QLQ‐BRECON24 scales and items differentiated between patient groups defined by clinical criteria, such as type and timing of reconstruction, postmastectomy radiotherapy and surgical complications, with moderate effect sizes. Prospectively, sexuality and surgical side‐effects scales showed significant responsiveness over time (
The QLQ‐BRECON23 is an internationally validated tool to be used alongside the EORTC QLQ‐C30 (cancer) and QLQ‐BR23 (breast cancer) questionnaires for evaluating quality of life and satisfaction after breast reconstruction.Read more
You may also be interested in
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target for TNBC?
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics
Authors: M. Ahmed, M. Douek
Risk of death from breast cancer after treatment for ductal carcinoma in situ. BJS 2017; 104: 1506-1513.
Authors: C. Wadsten, H. Garmo, I. Fredriksson, M. Sund, F. Wärnberg
Notes: Rare, but worse for large tumours and uncertain margins
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery. BJS 2017; 104: 1802-1810.
Authors: E. Botteri, P. Veronesi, J. Vila, N. Rotmensz, V. Galimberti, M. V. Thomazini et al.
Notes: Molecular subtype matters most
Authors: R. N. Pedersen, K. Bhaskaran, U. Heide‐Jørgensen, M. Nørgaard, P. M. Christiansen, N. Kroman et al.
Notes: No correlation
Nomograms for preoperative prediction of axillary nodal status in breast cancer. BJS 2017; 104: 1494-1505.
Authors: L. Dihge, P.‐O. Bendahl, L. Rydén
Notes: Defines need for staging?
Authors: J. R. Benson, S. K. Down
Authors: R. V. Dave, R. Millican‐Slater, D. Dodwell, K. Horgan, N. Sharma
Notes: Mid‐neoadjuvant chemotherapy MRI useful
Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node‐positive breast cancer after neoadjuvant therapy. BJS 2017; 104: 1188-1196.
Authors: B. B. Koolen, M. Donker, M. E. Straver, M. E. M. van der Noordaa, E. J. T. Rutgers, R. A. Valdés Olmos et al.
Notes: Reduced axillary lymph node dissection rates
Quality of life after mastectomy with or without immediate breast reconstruction. BJS 2017; 104: 1197-1206.
Authors: J. Dauplat, F. Kwiatkowski, P. Rouanet, E. Delay, K. Clough, J. L. Verhaeghe et al.
Notes: Good for the appropriate patient